Mechanistic Analysis of Drug Linker Clearance During Ultrafiltration/Diafiltration of an Antibody–Drug Conjugate
Biotechnology and Bioengineering · 2026-08-21
DOI: 10.1002/bit.70357 ↗At a glance
Journal article in Biotechnology and Bioengineering, published online on 2026-08-21. Written by Vasudev Tangry and 5 co-authors. Institution: Department of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania, USA. 22 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Science Foundation.
Abstract (original language)
Ultrafiltration/diafiltration (UF/DF) is a key unit operation in the manufacture of antibody‐drug conjugates (ADCs), commonly utilized for post‐conjugation purification to remove residual Drug Linker (DL) compounds and affect buffer exchange. The clearance of residual drug linker (DL), however, is often well below that predicted by ideal diafiltration theory. This work provides the first detailed mechanistic analysis of the factors that influence DL clearance during constant volume diafiltration, with particular emphasis on antibody concentration, membrane properties, and operating conditions. Diafiltration experiments in both stirred cell and tangential flow filtration systems demonstrate that DL sieving coefficients decrease with increasing ADC concentration and with increasing filtrate flux. These trends are quantitatively described using a newly developed diafiltration model accounting for intermolecular association between the hydrophobic DL and the ADC, with the ADC concentration at the membrane surface evaluated using the classical concentration polarization analysis. Experimental data obtained over a range of conditions are well‐described using this concentration polarization‐binding model. The model not only explains DL clearance data, but it also provides a framework for effective process design of UF/DF processes to ensure the required levels of DL clearance during ADC purification.
Subjects
Author keywords
Authors and institutions
- Department of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania, USA.
- AbbVie Inc., North Chicago, Illinois, USA.
ORCID profiles: Andrew L Zydney
Funding
- National Science Foundation
Cite
APA
Tangry, V., Lyu, F., Le, A., Mlinar, L., Kelkar, M. S., & Zydney, A. L. (2026). Mechanistic Analysis of Drug Linker Clearance During Ultrafiltration/Diafiltration of an Antibody–Drug Conjugate. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.70357
Vancouver
Tangry V, Lyu F, Le A, Mlinar L, Kelkar MS, Zydney AL. Mechanistic Analysis of Drug Linker Clearance During Ultrafiltration/Diafiltration of an Antibody–Drug Conjugate. Biotechnology and Bioengineering. 2026. doi:10.1002/bit.70357
BibTeX
@article{Tangry2026,
author = {Tangry, Vasudev and Lyu, Fara and Le, Amy and Mlinar, Laurie and Kelkar, Manish S and Zydney, Andrew L},
title = {Mechanistic Analysis of Drug Linker Clearance During Ultrafiltration/Diafiltration of an Antibody–Drug Conjugate},
journal = {Biotechnology and Bioengineering},
year = {2026},
doi = {10.1002/bit.70357}
}
EUVIMED